IN8bio reports FY2025 net loss $19.4M; GBM trial shows 97% PFS improvement

IN8BIO, INC.

Net loss $19.4M ($4.44/share) vs $30.4M ($17.05/share) prior year; cash $27.1M vs $11.1M year-end 2024.
Updated GBM data: mPFS 13.0 months for DRI patients vs 6.6 months SOC (+97%); mOS not yet reached at 17.2+ months.
Closed initial $20.1M of $40.2M private placement; net proceeds $18.5M extend cash runway into H1 2027.
Kate Rochlin promoted to President and COO in February 2026.
Anticipates FDA guidance on regulatory pathway for GBM program by H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IN8BIO, INC. reported financial results for fourth quarter and fiscal year ended December 31, 2025.

Period: fourth quarter and fiscal year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 12, 2026, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for fourth quarter and fiscal year ended December 31, 2025.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-104144

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.